For: | Chrysavgis L, Giannakodimos I, Diamantopoulou P, Cholongitas E. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World J Gastroenterol 2022; 28(3): 310-331 [PMID: 35110952 DOI: 10.3748/wjg.v28.i3.310] |
---|---|
URL: | https://www.wjgnet.com/1948-5204/full/v28/i3/310.htm |
Number | Citing Articles |
1 |
Darine Daher, Karim Seif El Dahan, Amit G. Singal. Non-alcoholic fatty liver disease-related hepatocellular carcinoma. Journal of Liver Cancer 2023; 23(1): 127 doi: 10.17998/jlc.2022.12.30
|
2 |
Triada Bali, Lampros Chrysavgis, Evangelos Cholongitas. Metabolic-Associated Fatty Liver Disease and Sarcopenia. Endocrinology and Metabolism Clinics of North America 2023; 52(3): 497 doi: 10.1016/j.ecl.2023.02.004
|
3 |
Ming Ren Toh, Evelyn Yi Ting Wong, Sunny Hei Wong, Alvin Wei Tian Ng, Lit-Hsin Loo, Pierce Kah-Hoe Chow, Joanne Ngeow. Global Epidemiology and Genetics of Hepatocellular Carcinoma. Gastroenterology 2023; 164(5): 766 doi: 10.1053/j.gastro.2023.01.033
|
4 |
Francesco Calabrese, Vittoria Disciglio, Isabella Franco, Paolo Sorino, Caterina Bonfiglio, Antonella Bianco, Angelo Campanella, Tamara Lippolis, Pasqua Pesole, Maurizio Polignano, Mirco Vacca, Giusy Caponio, Gianluigi Giannelli, Maria De Angelis, Alberto Osella. A Low Glycemic Index Mediterranean Diet Combined with Aerobic Physical Activity Rearranges the Gut Microbiota Signature in NAFLD Patients. Nutrients 2022; 14(9): 1773 doi: 10.3390/nu14091773
|
5 |
Pardis Habibi, Kimia Falamarzi, Niloofar Dehdari Ebrahimi, Mohammad Zarei, Mahdi Malekpour, Negar Azarpira. GDF11: An emerging therapeutic target for liver diseases and fibrosis. Journal of Cellular and Molecular Medicine 2024; 28(7) doi: 10.1111/jcmm.18140
|
6 |
J. Fu, Z. Mu, L. Sun, X. Gao, X. Hu, S. Xiu. Chinese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease have lower serum osteocalcin levels compared to individuals with type 2 diabetes mellitus and no liver disease: a single-center cross-sectional study. Journal of Endocrinological Investigation 2022; 45(12): 2275 doi: 10.1007/s40618-022-01861-z
|
7 |
Deng Lin, Yuling Song. Dapagliflozin Presented Nonalcoholic Fatty Liver Through Metabolite
Extraction and AMPK/NLRP3 Signaling Pathway. Hormone and Metabolic Research 2023; 55(01): 75 doi: 10.1055/a-1970-3388
|
8 |
Mamoun Younes, Lin Zhang, Baharan Fekry, Kristin Eckel-Mahan. Expression of p-STAT3 and c-Myc correlates with P2-HNF4α expression in nonalcoholic fatty liver disease (NAFLD). Oncotarget 2022; 13(1): 1308 doi: 10.18632/oncotarget.28324
|
9 |
Ying Zhao, Yanni Zhou, Dan Wang, Ziwei Huang, Xiong Xiao, Qing Zheng, Shengfu Li, Dan Long, Li Feng. Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD). International Journal of Molecular Sciences 2023; 24(24): 17514 doi: 10.3390/ijms242417514
|
10 |
Xin Su, Junjie Fu, Jing Hu, Honglei Jian, Shuo Bai, Jian Yin, Qingjun You. Effective photothermal-photodynamic treatment of hepatocellular carcinoma based on polydopamine-coated mesoporous silica nanoparticles. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2024; 693: 133931 doi: 10.1016/j.colsurfa.2024.133931
|
11 |
Jing Shu, Mingjie Zhang, Xiaocong Dong, Jingan Long, Yunshan Li, Peishan Tan, Tongtong He, Edward L Giovannucci, Xuehong Zhang, Zhongguo Zhou, Yanjun Xu, Xiaojun Xu, Tianyou Peng, Jialin Lu, Minshan Chen, Huilian Zhu, Yaojun Zhang, Aiping Fang. Vitamin D receptor gene polymorphisms, bioavailable 25-hydroxyvitamin D, and hepatocellular carcinoma survival. JNCI: Journal of the National Cancer Institute 2024; 116(10): 1687 doi: 10.1093/jnci/djae116
|
12 |
Wanshuang Lou, Chaoju Gong, Zhuoni Ye, Ynayan Hu, Minjing Zhu, Zejun Fang, Huihui Xu. Lipid metabolic features of T cells in the Tumor Microenvironment. Lipids in Health and Disease 2022; 21(1) doi: 10.1186/s12944-022-01705-y
|
13 |
Pinggui Chen, Yaoxuan Li, Yunyan Dai, Zhiming Wang, Yunpeng Zhou, Yi Wang, Gaopeng Li. Advances in the Pathogenesis of Metabolic Liver Disease-Related Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 2024; : 581 doi: 10.2147/JHC.S450460
|
14 |
Masanori Oshi, Kohei Chida, Arya Mariam Roy, Gabriella Kim Mann, Nan An, Li Yan, Itaru Endo, Kazuaki Takabe. Higher inflammatory response in hepatocellular carcinoma is associated with immune cell infiltration and a better outcome. Hepatology International 2024; 18(4): 1299 doi: 10.1007/s12072-024-10678-2
|
15 |
Lampros Chrysavgis, Grigorios Papadopoulos, Antonios Chatzigeorgiou. Hepatobiliary Cancers: An Interdisciplinary Approach. Interdisciplinary Cancer Research 2022; 3: 167 doi: 10.1007/16833_2022_87
|
16 |
Francesco Maria Calabrese, Giuseppe Celano, Caterina Bonfiglio, Angelo Campanella, Isabella Franco, Alessandro Annunziato, Gianluigi Giannelli, Alberto Ruben Osella, Maria De Angelis. Synergistic Effect of Diet and Physical Activity on a NAFLD Cohort: Metabolomics Profile and Clinical Variable Evaluation. Nutrients 2023; 15(11): 2457 doi: 10.3390/nu15112457
|
17 |
Qiang Wan, Sang Luo, Qiwen Lu, Chengyan Guan, Hao Zhang, Zhiyan Deng. Protective effects of puerarin on metabolic diseases: Emphasis on the therapeutical effects and the underlying molecular mechanisms. Biomedicine & Pharmacotherapy 2024; 179: 117319 doi: 10.1016/j.biopha.2024.117319
|
18 |
Paulina Pettinelli, Tiziana Fernández, Carolina Aguirre, Francisco Barrera, Arnoldo Riquelme, Rodrigo Fernández-Verdejo. Prevalence of non-alcoholic fatty liver disease and its association with lifestyle habits in adults in Chile: a cross-sectional study from the National Health Survey 2016–2017. British Journal of Nutrition 2023; 130(6): 1036 doi: 10.1017/S0007114523000028
|
19 |
Jinfei Yang, Weiwei Yao, Huihui Yang, Yajing Shen, Yuanyuan Zhang. Design and synthesis of ERα agonists: Effectively reduce lipid accumulation. Frontiers in Chemistry 2022; 10 doi: 10.3389/fchem.2022.1104249
|
20 |
Lampros G. Chrysavgis, Spyridon Kazanas, Konstantina Bafa, Sophia Rozani, Maria-Evangelia Koloutsou, Evangelos Cholongitas. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature. International Journal of Molecular Sciences 2024; 25(7): 3832 doi: 10.3390/ijms25073832
|
21 |
Supatsri Sethasine, Chadakarn Phaloprakarn. Relationship between breastfeeding and hepatic steatosis in women with previous gestational diabetes mellitus. International Breastfeeding Journal 2024; 19(1) doi: 10.1186/s13006-024-00684-3
|
22 |
Ornella Urzì, Roberta Gasparro, Elisa Costanzo, Angela De Luca, Gianluca Giavaresi, Simona Fontana, Riccardo Alessandro. Three-Dimensional Cell Cultures: The Bridge between In Vitro and In Vivo Models. International Journal of Molecular Sciences 2023; 24(15): 12046 doi: 10.3390/ijms241512046
|
23 |
Ilias D. Vachliotis, Ioannis Valsamidis, Stergios A. Polyzos. Tumor Necrosis Factor-Alpha and Adiponectin in Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma. Cancers 2023; 15(21): 5306 doi: 10.3390/cancers15215306
|
24 |
Yuan Ni, Maoqing Lu, Ming Li, Xixi Hu, Feng Li, Yan Wang, Dong Xue. Unraveling the underlying pathogenic factors driving nonalcoholic steatohepatitis and hepatocellular carcinoma: an in-depth analysis of prognostically relevant gene signatures in hepatocellular carcinoma. Journal of Translational Medicine 2024; 22(1) doi: 10.1186/s12967-024-04885-6
|
25 |
Haider Ghazanfar, Nismat Javed, Abeer Qasim, George Sarin Zacharia, Ali Ghazanfar, Abhilasha Jyala, Elona Shehi, Harish Patel. Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review. Cancers 2024; 16(6): 1214 doi: 10.3390/cancers16061214
|
26 |
Tarana Gupta. Nonalcoholic steatohepatitis and hepatocellular carcinoma: Beyond the boundaries of the liver. World Journal of Gastroenterology 2022; 28(36): 5380-5382 doi: 10.3748/wjg.v28.i36.5380
|
27 |
Satender Pal Singh, Vinod Arora, Tushar Madke, Shiv Kumar Sarin. Hepatocellular Carcinoma—Southeast Asia Updates. The Cancer Journal 2023; 29(5): 259 doi: 10.1097/PPO.0000000000000684
|
28 |
Jesús Rivera-Esteban, Sergio Muñoz-Martínez, Mónica Higuera, Elena Sena, María Bermúdez-Ramos, Juan Bañares, María Martínez-Gomez, M. Serra Cusidó, Alba Jiménez-Masip, Sven M. Francque, Frank Tacke, Beatriz Minguez, Juan M. Pericàs. Phenotypes of Metabolic Dysfunction–Associated Steatotic Liver Disease–Associated Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology 2024; 22(9): 1774 doi: 10.1016/j.cgh.2024.03.028
|
29 |
Souvik Sarkar, Aniket Alurwar, Carole Ly, Cindy Piao, Rajiv Donde, Christopher J. Wang, Frederick J. Meyers. A Machine Learning Model to Predict Risk for Hepatocellular Carcinoma in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. Gastro Hep Advances 2024; 3(4): 498 doi: 10.1016/j.gastha.2024.01.007
|
30 |
Fadi Abu Baker, Abdel-Rauf Zeina, Randa Taher, Saif Abu Mouch, Ariel Israel. Characterizing Unique Clinical and Virological Profiles in Concurrent Chronic Hepatitis B and Metabolic Dysfunction-Associated Liver Disease: Insights from a Population-Based Cohort Study. Journal of Clinical Medicine 2024; 13(18): 5608 doi: 10.3390/jcm13185608
|
31 |
Wakana Iwasaki, Ryo Yoshida, Hongxia Liu, Shota Hori, Yuki Otsubo, Yasutake Tanaka, Masao Sato, Satoshi Ishizuka. The ratio of 12α to non-12-hydroxylated bile acids reflects hepatic triacylglycerol accumulation in high-fat diet-fed C57BL/6J mice. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-20838-9
|
32 |
Stefan W. Ryter. Heme Oxygenase-1: An Anti-Inflammatory Effector in Cardiovascular, Lung, and Related Metabolic Disorders. Antioxidants 2022; 11(3): 555 doi: 10.3390/antiox11030555
|
33 |
Xinrong Li, Zhixiang Hu, Qili Shi, Wenying Qiu, Yizhe Liu, Yanfang Liu, Shenglin Huang, Linhui Liang, Zhiao Chen, Xianghuo He. Elevated choline drives KLF5-dominated transcriptional reprogramming to facilitate liver cancer progression. Oncogene 2024; 43(42): 3121 doi: 10.1038/s41388-024-03150-w
|
34 |
Qiongbo Wu, Zihao Chen, Yi Ding, Yunting Tang, Yawei Cheng. Protective effect of traditional Chinese medicine on non-alcoholic fatty liver disease and liver cancer by targeting ferroptosis. Frontiers in Nutrition 2022; 9 doi: 10.3389/fnut.2022.1033129
|
35 |
Rokas Stulpinas, Mindaugas Morkunas, Allan Rasmusson, Julius Drachneris, Renaldas Augulis, Aiste Gulla, Kestutis Strupas, Arvydas Laurinavicius. Improving HCC Prognostic Models after Liver Resection by AI-Extracted Tissue Fiber Framework Analytics. Cancers 2023; 16(1): 106 doi: 10.3390/cancers16010106
|
36 |
Grigorios Papadopoulos, Eirini Giannousi, Aikaterini P. Avdi, Rallia-Iliana Velliou, Polyxeni Nikolakopoulou, Antonios Chatzigeorgiou. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma. Frontiers in Cell and Developmental Biology 2024; 12 doi: 10.3389/fcell.2024.1343806
|
37 |
Yinghui Gao, Ruirui Zhu, Jianxia Dong, Zhiqin Li. Pathogenesis of NAFLD-Related Hepatocellular Carcinoma: An Up-to-Date Review. Journal of Hepatocellular Carcinoma 2023; : 347 doi: 10.2147/JHC.S400231
|
38 |
Praveenkumar Shetty, Pavan K. Jayaswamy, Prakash Patil, M. Vijaykrishnaraj, Jamboor K. Vishwanatha, Sukanya Shetty. Cardiometabolic Diseases. 2025; : 159 doi: 10.1016/B978-0-323-95469-3.00029-2
|
39 |
Mickaël Jouve, Rodolphe Carpentier, Sarra Kraiem, Noémie Legrand, Cyril Sobolewski. MiRNAs in Alcohol-Related Liver Diseases and Hepatocellular Carcinoma: A Step toward New Therapeutic Approaches?. Cancers 2023; 15(23): 5557 doi: 10.3390/cancers15235557
|
40 |
Hanyuan Liu, Xiao Li, Chenwei Zhang, Xiaopei Hao, Yongfang Cao, Yuliang Wang, Hao Zhuang, Na Yu, Tian Huang, Chuan Liu, Hengsong Cao, Zhengqing Lu, Jinhua Song, Li Liu, Hanjin Wang, Zhouxiao Li, Weiwei Tang. GJB2 Promotes HCC Progression by Activating Glycolysis Through Cytoplasmic Translocation and Generating a Suppressive Tumor Microenvironment Based on Single Cell RNA Sequencing. Advanced Science 2024; 11(39) doi: 10.1002/advs.202402115
|